Akhil Alugupalli

Series B Investor at OcuTerra Therapeutics - Boston, MA, US

Akhil Alugupalli's Colleagues at OcuTerra Therapeutics
Scott Edwards

President and Chief Development Officer

Contact Scott Edwards

David Tanzer

Chief Medical Officer | Executive Vice President - Clinical and Medical Affairs

Contact David Tanzer

Alexis Meng

Director Of Business Operations

Contact Alexis Meng

Kerrie Brady

Chief Executive Officer

Contact Kerrie Brady

Majid Anderesi

Vice President Clinical and Medical Affairs

Contact Majid Anderesi

Akhil Alugupalli's Contact Details
HQ
N/A
Location
Philadelphia,Pennsylvania,United States
Company
OcuTerra Therapeutics
Akhil Alugupalli's Company Details
OcuTerra Therapeutics logo, OcuTerra Therapeutics contact details

OcuTerra Therapeutics

Boston, MA, US • 5 - 9 Employees
Other

Non-Invasive, Transformational Approach to Treating Retinal Disease.OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

N/A
Details about OcuTerra Therapeutics
Frequently Asked Questions about Akhil Alugupalli
Akhil Alugupalli currently works for OcuTerra Therapeutics.
Akhil Alugupalli's role at OcuTerra Therapeutics is Series B Investor.
Akhil Alugupalli's email address is ***@. To view Akhil Alugupalli's full email address, please signup to ConnectPlex.
Akhil Alugupalli works in the Research industry.
Akhil Alugupalli's colleagues at OcuTerra Therapeutics are Scott Edwards, David Tanzer, Alexis Meng, Kerrie Brady, Majid Anderesi and others.
Akhil Alugupalli's phone number is N/A
See more information about Akhil Alugupalli